We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
Back
Tag:
Tag:
glp-1
1 studies
Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial
by Asger Wretlind, Andressa de Zawadzki, Rasmus Sejersten Ripa, Viktor Rotbain Curovic, Bernt Johan von Scholten, Ismo Matias Mattila, Tine Willum Hansen, Andreas Kjær, Peter Rossing, Cristina Legido-Quigley
Liraglutide, a GLP-1 agonist medication, was given to obese and diabetic (type 2) patients. Lipids were analyzed subsequently. In these patients, palmitoleic acid was decreased after taking the medication vs. placebo. This could indicate lower de novo lipogenesis.